🏛️ Verified NIH Record • Updated 2026-08-12
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran (NCT07553442)
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Alnylam Pharmaceuticals
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — Lake Forest, California
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- Clinical Trial Site — Lake Forest, California
- Clinical Trial Site — Tampa, Florida
- Clinical Trial Site — Savannah, Georgia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.